BHCM
ANGO icon

Brevan Howard Capital Management’s AngioDynamics ANGO Stock Holding History

Brevan Howard Capital Management’s Portfolio ANGO Stock Details ANGO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-12,781
Closed -$164K – 2129
2025
Q4 		$164K Buy
+12,781
New +$158K ﹤0.01% 1623
2024
Q4 		– Sell
-20,964
Closed -$163K – 1024
2024
Q3 		$163K Buy
20,964
+10,686
+104% +$77.2K ﹤0.01% 1031
2024
Q2 		$62.2K Buy
+10,278
New +$63.4K ﹤0.01% 998
2024
Q1 		– Sell
-19,048
Closed -$149K – 997
2023
Q4 		$149K Buy
+19,048
New +$132K ﹤0.01% 916

Other funds holding ANGO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SFM
Systematic Financial Management Teaneck, New Jersey $4.36B AUM 40.56% 1-Year Est. Return
BH
Broadfin Holdings Melville, New York $23.5M AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
WCM
Weber Capital Management San Francisco, California $100M AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BAM
Bastion Asset Management Montreal, Canada $328M AUM 13.57% 1-Year Est. Return

Brevan Howard Capital Management's ANGO Position: Q1 2026 in Review

Brevan Howard Capital Management sold out of AngioDynamics (ANGO) in Q1 2026, closing a stake of 12,781 shares — an estimated $164K sold.

Brevan Howard Capital Management first reported a position in ANGO in Q4 2023 and held it in 4 quarters. The position peaked at $164K in Q4 2025. 147 funds tracked by Wall St. Rank hold ANGO as of Q1 2026.

  • Brevan Howard Capital Management reported no remaining AngioDynamics position as of Q1 2026 after selling out during the quarter.
  • Brevan Howard Capital Management sold 12,781 AngioDynamics shares in Q1 2026, an estimated $164K.
  • Brevan Howard Capital Management first reported a position in AngioDynamics in Q4 2023 and held it in 4 quarters.
  • Brevan Howard Capital Management's AngioDynamics position peaked at $164K in Q4 2025.
  • 147 funds tracked by Wall St. Rank held AngioDynamics as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.